ArticleBMC endocrine disorders2025
Metabolic score for visceral fat and atrial fibrillation risk: a prospective study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe metabolic score for visceral fat (METS-VF), which integrates measures of visceral adiposity, insulin resistance, and demographic variables, serves as a composite indicator of metabolic health. However, the association between METS-VF and atrial fibrillation (AF) risk is unclear. This study aimed to investigate the prospective association between METS-VF and incident AF within the UK Biobank cohort.
methodsA total of 400,668 participants from the UK Biobank were included in the analysis. Flexible parametric survival models were applied to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between METS-VF and AF incidence. Additional subgroup and sensitivity analyses were conducted to evaluate the consistency of the results.
resultsOver a cumulative follow-up of 62,789,030 person-months, 28,764 individuals were diagnosed with AF. In multivariable-adjusted models, elevated METS-VF levels were significantly associated with a heightened risk of AF, with an adjusted HR of 1.38 (95% CI, 1.34-1.42). When stratified by METS-VF quartiles, the adjusted HRs for the second, third, and fourth quartiles were 1.08 (95% CI, 1.03-1.12), 1.14 (95% CI, 1.09-1.19), and 1.44 (95% CI, 1.37-1.50), respectively (P for trend < 0.001). The association remained stable across multiple sensitivity analyses.
conclusionsElevated METS-VF is independently linked to a greater risk of incident AF. These findings underscore the potential utility of METS-VF as a clinical marker for early identification of individuals at elevated AF risk, supporting its role in targeted prevention and personalized cardiovascular risk management. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.